An observational study in Seroma, Necrosis and Infection, sponsored by Baxter Healthcare Corporation. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-05.
Sponsored by Baxter Healthcare Corporation · Observational
Retrospective data collection of the use of Veritas in breast reconstruction surgery
This is a multi-center study to retrospectively collect data on the use of Veritas Collagen Matrix in breast reconstruction. Data will be collected on post-operative complications in immediate breast reconstruction and then be compared to literature reported post-operative complication rates associated with the use of acellular dermal matrix in immediate breast reconstruction.
477 studies on the registry are indexed under Necrosis; 54 are open to participants now.
This study's enrollment of 54 is below the median of 100 across 147 observational studies indexed under Necrosis.
Browse Necrosis studies →Baxter Healthcare Corporation is the lead sponsor of 78 studies on the registry; 1 is open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.
Counted across the registry records on this site, refreshed daily.
Consecutive patients who have undergone single-stage or two-stage breast reconstruction surgery with Veritas
Exclusion Criteria:
Breast reconstruction with Veritas
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Baxter Healthcare Corporation